Dear Editor,

We have read with interest the letter by Kollias et al.[@bib0001] as a commentary on our recent meta-analysis on the prognostic role of cardiac troponins in coronavirus disease 2019 (COVID-19) patients.[@bib0002]

While our meta-analysis included studies published until April 30, 2020 only, Kollias et al. analysed studies published through May 30, 2020. The resultant final outcomes of both meta-analyses were similar regarding the impact of troponins on mortality (hazard ratios (HR) with corresponding 95% confidence intervals were 2.48 (1.50--4.11) and 2.3 (1.3-4.1) for the studies of Vrsalovic et al., and Kollias et al., respectively). The only difference was a significant heterogeneity observed in the study of Kollias et al. (Cochran *Q* = 7.14, *p* = 0.03) compared to the study of Vrsalovic et al. (Cochran *Q* = 4.17, *p* = 0.12) which requires further clarification.

In a study by Petrilli et al. (that was included in the meta-analysis of Kollias et al.) HRs of hospital mortality were reported for two groups of increased troponin values (i.e. 0.1--1 ng/mL, and \>1 ng/mL), and the troponin cut-off (0.1 ng/mL) was approximately 5--6 times higher compared to other studies included in the meta-analysis.[@bib0003] In our meta-analysis, cardiac injury was defined as serum troponin levels above the 99th percentile upper reference limit. Kollias et al. pooled the hazard ratios reported in the study, but the method of pooling the data to "study-unique" HR was not explained in the letter. Meta-analysis is used to derive a consolidated estimate of individual studies, and inclusion of *post hoc* pooled estimates (instead of raw data analysis) may result in an increased heterogeneity. Moreover, in the study of Petrilli et al. a competing risk model for the mortality or hospice outcome was performed. Hospital discharge was considered to be a competing risk, since mortality data were limited after that point unless the patient was readmitted into the hospital system. As such, the inclusion of this study in the meta-analysis (i.e. meta-analysis investigated the impact of cardiac injury in terms of mortality) can be questioned.

The Kollias et al. meta-analysis included the study of Li et al. which included a sample of 548 patients.[@bib0004] The aforementioned cohort study included both non-severe and severe COVID-19 patients. Consequently, epidemiological, demographic and clinical characteristics of hospitalized patients with severe and non-severe disease were compared. However, the multivariable Cox regression analysis that identified factors associated with death was performed in only 269 severe patients (median age 65 years, interquartile range 54--72 years), and the results cannot be applied to the entire cohort, as was stated in the letter.

Based on the aforementioned methodological issues we performed an additional sub-analysis that included the two largest studies from Wuhan, China, which included 940 patients with COVID-19 ([Table 1](#tbl0001){ref-type="table"} ), accounting for the fact that both studies analysed hospitalized cases with severe and critical illness.[@bib0004] ^,^ [@bib0005] A total of 149 (16%) patients died during in-hospital stay, and positive cardiac troponin was present in 200 (21%) patients.Table 1Characteristics of studies included in meta-analysis.Table 1Author, yearCity, CountryNAge (years), median (IQR)Mortality (%)Troponin positive (%)Troponin cut-off (ng/mL)Adjusted HR (95% CI)Li X, 2020 (severe cases)Wuhan, China26965 (54--72)32.5350.01562.90 (1.80, 4.80)Shi S, 2020Wuhan, China67163 (50--72)9.2160.02604.56 (1.28, 16.28)[^1]

Meta-analysis of those studies that reported adjusted HR (using the generic inverse variance method and fixed effects model), showed a significant association between elevated troponin values and mortality (HR = 3.08; 95% CI 1.95--4.87) ([Fig. 1](#fig0001){ref-type="fig"} ), and no significant heterogeneity between studies was detected (Cochran *Q* = 0.44, *p* = 0.50).Fig. 1Forest plot of adjusted hazard ratios (HRs) for mortality associated with cardiac injury in patients with coronavirus disease 2019 (COVID-19).The meta-analysis was conducted using the generic inverse variance method, and pooled HR was reported with 95% confidence interval (CI). There was no significant heterogeneity observed across studies (Cochran *Q* = 0.44, *p* = 0.50).Fig 1

In conclusion, troponin positivity is common and has an independent prognostic role in hospitalised severe COVID-19 patients. Consequently cardiac injury may serve as an additional risk stratification tool in daily clinical setting.
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[^1]: CI, confidence interval; HR, hazard ratio; IQR, interquartile range.
